FDA Approves Repeat Treatment for iDose TR Glaucoma Implant
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
Mizuho upgrades Circle Internet to Neutral with $77 price target, citing USDC activity on Polymarket as a key growth catalyst.
Palladyne AI shares jumped 47% premarket after winning an Air Force contract to coordinate autonomous systems including satellites using its SwarmOS platform.
REGENXBIO shares drop 32% as FDA places clinical hold on two rare disease gene therapies following brain tumor discovery in trial participant.
Starbucks (SBUX) reports 4% global same-store sales growth for Q1, beating expectations as CEO Brian Niccol's turnaround strategy gains momentum with menu simplification and improved store experience.
AT&T surpasses Q4 profit estimates with best broadband growth in a decade. Stock jumps as company forecasts $45B+ shareholder returns through 2028.